Selected research
Market Structure
Global Short Bowel Syndrome (SBS) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Short Bowel Syndrome (SBS) Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Short Bowel Syndrome (SBS) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Short Bowel Syndrome (SBS) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Short Bowel Syndrome (SBS) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Short Bowel Syndrome (SBS) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Short Bowel Syndrome (SBS) Drugs include Takeda, Merck, Zealand Pharma, Sancilio Pharmaceuticals, OxThera, Nutrinia, Naia Pharmaceuticals, Emmaus Medical and Ardelyx, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Short Bowel Syndrome (SBS) Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Short Bowel Syndrome (SBS) Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Short Bowel Syndrome (SBS) Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Short Bowel Syndrome (SBS) Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Short Bowel Syndrome (SBS) Drugs Segment by Company
Takeda
Merck
Zealand Pharma
Sancilio Pharmaceuticals
OxThera
Nutrinia
Naia Pharmaceuticals
Emmaus Medical
Ardelyx
Short Bowel Syndrome (SBS) Drugs Segment by Type
Glutamine
Growth Hormone
Glucagon-Like Peptide-2 (GLP-2)
Other
Short Bowel Syndrome (SBS) Drugs Segment by Application
Hospitals
Clinics
Retail Pharmacies
Short Bowel Syndrome (SBS) Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Short Bowel Syndrome (SBS) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Short Bowel Syndrome (SBS) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Short Bowel Syndrome (SBS) Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Short Bowel Syndrome (SBS) Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Short Bowel Syndrome (SBS) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Short Bowel Syndrome (SBS) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Short Bowel Syndrome (SBS) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Glutamine
- Growth Hormone
- Glucagon-Like Peptide-2 (GLP-2)
- Other
Applications
- Hospitals
- Clinics
- Retail Pharmacies
Companies covered
- Takeda
- Merck
- Zealand Pharma
- Sancilio Pharmaceuticals
- OxThera
- Nutrinia
- Naia Pharmaceuticals
- Emmaus Medical
- Ardelyx
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Short Bowel Syndrome (SBS) Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Short Bowel Syndrome (SBS) Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Short Bowel Syndrome (SBS) Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Short Bowel Syndrome (SBS) Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Short Bowel Syndrome (SBS) Drugs Market Dynamics
- 2.1 Short Bowel Syndrome (SBS) Drugs Industry Trends
- 2.2 Short Bowel Syndrome (SBS) Drugs Industry Drivers
- 2.3 Short Bowel Syndrome (SBS) Drugs Industry Opportunities and Challenges
- 2.4 Short Bowel Syndrome (SBS) Drugs Industry Restraints
3 Short Bowel Syndrome (SBS) Drugs Market by Manufacturers
- 3.1 Global Short Bowel Syndrome (SBS) Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global Short Bowel Syndrome (SBS) Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global Short Bowel Syndrome (SBS) Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Short Bowel Syndrome (SBS) Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Short Bowel Syndrome (SBS) Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Short Bowel Syndrome (SBS) Drugs Manufacturers, Product Type & Application
- 3.7 Global Short Bowel Syndrome (SBS) Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Short Bowel Syndrome (SBS) Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Short Bowel Syndrome (SBS) Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 Short Bowel Syndrome (SBS) Drugs Tier 1, Tier 2, and Tier 3
4 Short Bowel Syndrome (SBS) Drugs Market by Type
- 4.1 Short Bowel Syndrome (SBS) Drugs Type Introduction
- 4.1.1 Glutamine
- 4.1.2 Growth Hormone
- 4.1.3 Glucagon-Like Peptide-2 (GLP-2)
- 4.1.4 Other
- 4.2 Global Short Bowel Syndrome (SBS) Drugs Sales by Type
- 4.2.1 Global Short Bowel Syndrome (SBS) Drugs Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Short Bowel Syndrome (SBS) Drugs Sales by Type (2021-2032)
- 4.2.3 Global Short Bowel Syndrome (SBS) Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global Short Bowel Syndrome (SBS) Drugs Revenue by Type
- 4.3.1 Global Short Bowel Syndrome (SBS) Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Short Bowel Syndrome (SBS) Drugs Revenue by Type (2021-2032)
- 4.3.3 Global Short Bowel Syndrome (SBS) Drugs Revenue Market Share by Type (2021-2032)
5 Short Bowel Syndrome (SBS) Drugs Market by Application
- 5.1 Short Bowel Syndrome (SBS) Drugs Application Introduction
- 5.1.1 Hospitals
- 5.1.2 Clinics
- 5.1.3 Retail Pharmacies
- 5.2 Global Short Bowel Syndrome (SBS) Drugs Sales by Application
- 5.2.1 Global Short Bowel Syndrome (SBS) Drugs Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Short Bowel Syndrome (SBS) Drugs Sales by Application (2021-2032)
- 5.2.3 Global Short Bowel Syndrome (SBS) Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global Short Bowel Syndrome (SBS) Drugs Revenue by Application
- 5.3.1 Global Short Bowel Syndrome (SBS) Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Short Bowel Syndrome (SBS) Drugs Revenue by Application (2021-2032)
- 5.3.3 Global Short Bowel Syndrome (SBS) Drugs Revenue Market Share by Application (2021-2032)
6 Global Short Bowel Syndrome (SBS) Drugs Sales by Region
- 6.1 Global Short Bowel Syndrome (SBS) Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Short Bowel Syndrome (SBS) Drugs Sales by Region (2021-2032)
- 6.2.1 Global Short Bowel Syndrome (SBS) Drugs Sales by Region (2021-2026)
- 6.2.2 Global Short Bowel Syndrome (SBS) Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Short Bowel Syndrome (SBS) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Short Bowel Syndrome (SBS) Drugs Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Short Bowel Syndrome (SBS) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Short Bowel Syndrome (SBS) Drugs Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Short Bowel Syndrome (SBS) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Short Bowel Syndrome (SBS) Drugs Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Short Bowel Syndrome (SBS) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Short Bowel Syndrome (SBS) Drugs Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Short Bowel Syndrome (SBS) Drugs Revenue by Region
- 7.1 Global Short Bowel Syndrome (SBS) Drugs Revenue by Region
- 7.1.1 Global Short Bowel Syndrome (SBS) Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Short Bowel Syndrome (SBS) Drugs Revenue by Region (2021-2026)
- 7.1.3 Global Short Bowel Syndrome (SBS) Drugs Revenue by Region (2027-2032)
- 7.1.4 Global Short Bowel Syndrome (SBS) Drugs Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Short Bowel Syndrome (SBS) Drugs Revenue (2021-2032)
- 7.2.2 North America Short Bowel Syndrome (SBS) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Short Bowel Syndrome (SBS) Drugs Revenue (2021-2032)
- 7.3.2 Europe Short Bowel Syndrome (SBS) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Short Bowel Syndrome (SBS) Drugs Revenue (2021-2032)
- 7.4.2 Asia-Pacific Short Bowel Syndrome (SBS) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Short Bowel Syndrome (SBS) Drugs Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Short Bowel Syndrome (SBS) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Takeda
- 8.1.1 Takeda Company Information
- 8.1.2 Takeda Business Overview
- 8.1.3 Takeda Short Bowel Syndrome (SBS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Takeda Short Bowel Syndrome (SBS) Drugs Product Portfolio
- 8.1.5 Takeda Recent Developments
- 8.2 Merck
- 8.2.1 Merck Company Information
- 8.2.2 Merck Business Overview
- 8.2.3 Merck Short Bowel Syndrome (SBS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Merck Short Bowel Syndrome (SBS) Drugs Product Portfolio
- 8.2.5 Merck Recent Developments
- 8.3 Zealand Pharma
- 8.3.1 Zealand Pharma Company Information
- 8.3.2 Zealand Pharma Business Overview
- 8.3.3 Zealand Pharma Short Bowel Syndrome (SBS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Zealand Pharma Short Bowel Syndrome (SBS) Drugs Product Portfolio
- 8.3.5 Zealand Pharma Recent Developments
- 8.4 Sancilio Pharmaceuticals
- 8.4.1 Sancilio Pharmaceuticals Company Information
- 8.4.2 Sancilio Pharmaceuticals Business Overview
- 8.4.3 Sancilio Pharmaceuticals Short Bowel Syndrome (SBS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Sancilio Pharmaceuticals Short Bowel Syndrome (SBS) Drugs Product Portfolio
- 8.4.5 Sancilio Pharmaceuticals Recent Developments
- 8.5 OxThera
- 8.5.1 OxThera Company Information
- 8.5.2 OxThera Business Overview
- 8.5.3 OxThera Short Bowel Syndrome (SBS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 OxThera Short Bowel Syndrome (SBS) Drugs Product Portfolio
- 8.5.5 OxThera Recent Developments
- 8.6 Nutrinia
- 8.6.1 Nutrinia Company Information
- 8.6.2 Nutrinia Business Overview
- 8.6.3 Nutrinia Short Bowel Syndrome (SBS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Nutrinia Short Bowel Syndrome (SBS) Drugs Product Portfolio
- 8.6.5 Nutrinia Recent Developments
- 8.7 Naia Pharmaceuticals
- 8.7.1 Naia Pharmaceuticals Company Information
- 8.7.2 Naia Pharmaceuticals Business Overview
- 8.7.3 Naia Pharmaceuticals Short Bowel Syndrome (SBS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Naia Pharmaceuticals Short Bowel Syndrome (SBS) Drugs Product Portfolio
- 8.7.5 Naia Pharmaceuticals Recent Developments
- 8.8 Emmaus Medical
- 8.8.1 Emmaus Medical Company Information
- 8.8.2 Emmaus Medical Business Overview
- 8.8.3 Emmaus Medical Short Bowel Syndrome (SBS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Emmaus Medical Short Bowel Syndrome (SBS) Drugs Product Portfolio
- 8.8.5 Emmaus Medical Recent Developments
- 8.9 Ardelyx
- 8.9.1 Ardelyx Company Information
- 8.9.2 Ardelyx Business Overview
- 8.9.3 Ardelyx Short Bowel Syndrome (SBS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Ardelyx Short Bowel Syndrome (SBS) Drugs Product Portfolio
- 8.9.5 Ardelyx Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Short Bowel Syndrome (SBS) Drugs Value Chain Analysis
- 9.1.1 Short Bowel Syndrome (SBS) Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Short Bowel Syndrome (SBS) Drugs Production Mode & Process
- 9.2 Short Bowel Syndrome (SBS) Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Short Bowel Syndrome (SBS) Drugs Distributors
- 9.2.3 Short Bowel Syndrome (SBS) Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst